• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthOpioid Crisis

DEA Whistleblower Blasts Drug Distributors, Congress Over Opioid ‘Collusion’

By
David Meyer
David Meyer
and
Geoffrey Smith
Geoffrey Smith
Down Arrow Button Icon
By
David Meyer
David Meyer
and
Geoffrey Smith
Geoffrey Smith
Down Arrow Button Icon
October 16, 2017, 9:29 AM ET

The U.S.’s biggest drug distributors and some of its most senior politicians colluded to fuel the country’s opioid epidemic, leading directly to thousands of unnecessary deaths.

That was the conclusion of a former Drug Enforcement Agency official whose blistering testimony was carried on last night’s edition of 60 Minutes on CBS and in the Washington Post, which also participated in the investigation.

“This is an industry that’s out of control. If they don’t follow the law in drug supply, and diversion occurs, people die. That’s just it, people die,” Joe Rannazzisi, the former DEA agent turned whistleblower, told CBS. He’s now advising lawyers suing the opioid industry.

Rannazzisi singled out the country’s three biggest drug distribution companies for criticism: Cardinal Health (CAH), McKesson (MCK) and AmerisourceBergen (ABC). Together the three account for almost 90 percent of their market, he explained.

Read: Cigna Escalates War on Opioids With OxyContin Crackdown. Is It About Public Health or Business?

Bill Whitaker said he was implying that “these big companies knew that they were pumping drugs into American communities that were killing people.”

“That’s not an implication, that’s a fact,” Rannazzisi replied. “That’s exactly what they did…This is an industry that allowed millions and millions of drugs to go into bad pharmacies and doctors’ offices that distributed them out to people who had no legitimate need for those drugs.”

McKesson didn’t respond immediately to the allegations. Cardinal issued a statement saying that: “Our people care deeply about this issue and the devastation it has caused American families and communities. We will continue to work alongside regulators, manufacturers, prescribers, pharmacists, educators, patients and others to fight opioid abuse and addiction.” (For the full statement, click here).

AmerisourceBergen CEO Steve Collis argued in a recent blog post that distributors merely execute what is demanded from pharmacies and approved by the DEA.

“We report the quantity and details of every order of opioid-based medication we ship directly to the DEA on a daily basis,” Collis wrote. “We use complex algorithms to identify and stop orders that are deemed to be suspicious. In fact, we’ve reported and stopped tens of thousands of suspicious orders since 2007, not to mention the countless other orders that pharmacies never had the opportunity to place because we declined to service them altogether.”

The Healthcare Distribution Alliance, an industry lobby group, meanwhile argued in a statement that it had been raising concerns about prescription of painkillers for years but the DEA had failed to respond.

“Our industry has continuously sought opportunities to communicate and coordinate more effectively with DEA to better understand our reporting responsibilities under the Controlled Substances Act, and to work together to mitigate the opioid epidemic,” the HDA said. “Prior to 2016, these efforts were not reciprocated — as noted by the Government Accountability Office (GAO) in a July 2015 report.”

Read: Big Pharma Is Getting Hit With a Huge Wave of Opioid Suits

A law signed by then-president Barack Obama last year made it much more difficult for the Drug Enforcement Agency (DEA) to crack down on the illegal distribution and sale of prescription painkillers such as Vicodin and oxycodone, the investigation found.

The law in question, the Ensuring Patient Access and Effective Drug Enforcement Act, was championed by Republican congressman Tom Marino and—according to the story—largely written by D. Linden Barber, a former DEA lawyer who went on to work for the drug companies. Marino is currently Donald Trump’s pick to head the Office of National Drug Control Policy.

The law was supposed to aid enforcement by improving ties with industry. However, it made a crucial change to the standard required for the DEA to freeze drug shipments that it suspected were finding their way to addicts in opioid-ravaged communities. For four decades, the DEA could freeze shipments that posed an “imminent danger,” but the law changed that to “a substantial likelihood of an immediate threat.”

Read: As America’s Opioid Crisis Spirals, Giant Drug Distributor McKesson Is Feeling the Pain

The Washington Post noted that, in a draft article written for the Marquette Law Review, DEA chief administrative law judge John Mulrooney said the law “imposed a dramatic diminution of the agency’s authority” that made it “all but logically impossible” to stop a drug company distributing its wares for non-compliance with federal law.

According to the article, the White House did not appreciate the impact of the change when Obama signed the law. However, despite the fact that the opioid epidemic has reached the level of “national emergency,” not one order has been made against a distributor or manufacturer since late 2015.

The Post said it is currently suing the Justice Department to get its hands on public records that might clarify what happened.

The DEA said Monday that it was doing everything it could to fight the opioid epidemic. “During the past seven years, we have removed approximately 900 registrations annually, preventing reckless doctors and rogue businesses from making an already troubling problem worse,” it said in a statement. CBS also reported that the Justice Department did not dispute any of the 60 Minutes story.

UPDATE: This article has been updated to include comment from AmerisourceBergen and the HDA.

About the Authors
By David Meyer
LinkedIn icon
See full bioRight Arrow Button Icon
By Geoffrey Smith
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

school
North AmericaEducation
First and second graders born during their pandemic are worse at math and reading
By Moriah Balingit and The Associated PressMarch 10, 2026
24 hours ago
A woman in a red coat holds up a sign that says, “Shouldn’t hurt to be a nurse.”
EconomyLabor
Health care has been propping up a shaky labor market. For the first time in over four years, the sector shed thousands of jobs
By Sasha RogelbergMarch 9, 2026
2 days ago
stitch
Future of WorkSocial Media
‘It feels like a video game, but in real life’: Gen Z’s love of analog ‘grandma’ hobbies jump from Pokemon to bird-watching, scrolling to needlepoint
By Kaitlyn Huamani and The Associated PressMarch 9, 2026
2 days ago
HealthLongevity
From thyroid cancer to 40‑hour fasts: Inside Daymond John’s obsession with biohacking and living longer
By Sydney LakeMarch 8, 2026
3 days ago
AImental health
Chatbots are ‘constantly validating everything’ even when you’re suicidal. New research measures how dangerous AI psychosis really is
By Catherina GioinoMarch 7, 2026
4 days ago
adams
CommentaryVaccines
Trump’s former Surgeon General: voters widely support vaccine access and want Washington to focus elsewhere
By Jerome AdamsMarch 7, 2026
4 days ago

Most Popular

placeholder alt text
Economy
'This cannot be sustainable': The U.S. borrowed $50 billion a week for the past five months, the CBO says
By Eleanor PringleMarch 10, 2026
1 day ago
placeholder alt text
Future of Work
Shark Tank's Kevin O'Leary doesn't care if you work from your basement. He just wants to know if you can ‘execute’
By Marco Quiroz-GutierrezMarch 10, 2026
1 day ago
placeholder alt text
Real Estate
Billionaires Elon Musk and Mark Zuckerberg used mortgages to buy multimillion-dollar mansions. Here’s why that’s a savvy financial decision
By Sydney LakeMarch 9, 2026
2 days ago
placeholder alt text
Big Tech
Big tech has defeated everything for 30 years, but for the first time faces something it can't control: a jury
By Carolina Rossini and The ConversationMarch 10, 2026
19 hours ago
placeholder alt text
Politics
Washington state wants to keep employers from microchipping workers, before anyone even gets the idea
By Catherina GioinoMarch 10, 2026
20 hours ago
placeholder alt text
Economy
Trump's immigration crackdown is backfiring by hurting the U.S.-born workers it was meant to help, data shows
By Sasha RogelbergMarch 10, 2026
21 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.